Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes

Successful MYTHIC Trial:
Repare Therapeutics has announced positive results from its MYTHIC Phase 1 clinical trial, evaluating the combination of lunresertib and camonsertib for endometrial cancer and platinum-resistant ovarian cancer. The trial showed a 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer1 3.

Phase 3 Trial Plans:
Based on these results, Repare plans to initiate a Phase 3 trial for the drug combination in endometrial cancer in the second half of 2025. The company has received positive feedback from regulatory agencies in the U.S. and Europe1 3.

Cost-Effective Strategies:
The move aligns with broader industry efforts to streamline clinical trials and reduce costs. Strategies such as utilizing lower-cost facilities, in-home testing, patient recruitment and retention strategies, partnering with CROs, and optimizing protocol design can significantly reduce clinical trial costs without compromising trial quality2 5.

Financial Position:
Repare Therapeutics maintains a strong financial position with more cash than debt on its balance sheet, which supports its plans for the Phase 3 trial3.

Drug Combination:
The combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR kinase inhibitor) targets cell cycle regulation in tumors and has shown promising efficacy in gynecologic cancers1 4.